At the time of writing, Adaptive Biotechnologies Corp [ADPT] stock is trading at $13.75, up 0.29%. An important factor to consider is whether the stock is rising or falling in short-term value. The ADPT shares have lost -5.37% over the last week, with a monthly amount drifted -22.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptive Biotechnologies Corp [NASDAQ: ADPT] stock has seen the most recent analyst activity on September 30, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $20. Previously, Craig Hallum started tracking the stock with Buy rating on June 18, 2025, and set its price target to $15. On March 21, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $9 on the stock. Scotiabank initiated its recommendation with a Sector Outperform and recommended $15 as its price target on January 05, 2023. Piper Sandler upgraded its rating to Overweight for this stock on December 21, 2022, and upped its price target to $14. In a note dated August 25, 2022, Credit Suisse initiated an Underperform rating and provided a target price of $8 on this stock.
For the past year, the stock price of Adaptive Biotechnologies Corp fluctuated between $4.27 and $17.89. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $13.75 at the most recent close of the market. An investor can expect a potential return of 45.45% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
According to Adaptive Biotechnologies Corp [NASDAQ:ADPT], the company’s sales were 252.75M for trailing twelve months, which represents an 102.38% jump. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.59%, Pretax Profit Margin comes in at -0.59%, and Net Profit Margin reading is -0.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.61 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.37 points at the first support level, and at 12.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.04, and for the 2nd resistance point, it is at 14.33.
Ratios To Look Out For
It is important to note that Adaptive Biotechnologies Corp [NASDAQ:ADPT] has a current ratio of 3.38. On the other hand, the Quick Ratio is 3.26, and the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 8.31, the price to book ratio is 10.26.
Transactions by insiders
Recent insider trading involved PISKEL KYLE, Chief Financial Officer, that happened on Nov 17 ’25 when 238.0 shares were sold. Chief Scientific Officer, ROBINS HARLAN S completed a deal on Nov 10 ’25 to sell 10000.0 shares. Meanwhile, CEO and Chairman ROBINS CHAD M sold 86161.0 shares on Nov 10 ’25.
